|
Sponsored by 
|
|
|
|
|
|
|
By Nicholas Florko
Hans Pennink/AP
A number of pharmaceutical companies are shepherding their CBD-based products through the lengthy and expensive FDA approval process for medicine.
Read More
|
|
By Ed Silverman
Alex Hogan/STAT
This is only the latest episode in which a drug maker has accusied a former employee of walking out the door with confidential information.
Read More
|
|
By Sharon Begley
Mike Reddy for STAT
The most impactful intervention would be primary prevention — that is, keeping healthy brains from taking the first pathological steps toward Alzheimer’s.
Read More
|
|
Sponsor content by Cardinal Health
The data is in the details: Getting more from eBVs and ePAs
The automation of manual tasks is a trend seen across industries and its promise is particularly meaningful in health care, where faster processing of insurance benefits can expedite care. While the biopharma industry has focused on faster turnaround times possible with eBV and ePA technology, that’s just one of the promises automation has to offer. There’s an overlooked benefit that may be key to understanding the patient journey with more insight. See what you’ve been missing.
|
|
By Stephen J. Ubl
Zach Gibson/Getty Images
Lowering prescription drug costs for patients is a critical issue that must be addressed. House Speaker Nancy Pelosi's bill isn't the way to do it.
Read More
|
|
By Adam Feuerstein
September Dawn Bottoms for STAT
ArsenalBio aims to use CRISPR, synthetic biology, and other technologies to engineer immune cell therapies that can better find and kill cancer cells.
Read More
|
|
By Lev Facher
Win McNamee/Getty Images
Rep. Elijah Cummings, a longtime advocate for lower drug prices, passed away Thursday. Now Nancy Pelosi is naming Democrats’ drug pricing bill in his honor.
Read More
|
|
